Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

By sjmartinez • December 13, 2024

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 9:S2352-3018(24)00247-9. doi: 10.1016/S2352-3018(24)00247-9. Epub ahead of print. PMID: 39667379.

Tags: Infectious Diseases, Publications

Related Posts

Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity

Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson[...]

Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US

Pei PP, Jones M, Hu R, Chen W, Sax PE, Pandya A, Gandhi M, Eron JJ, Currier JS, Wilkin TJ, Reddy KP, Qoshe L, Hyle[...]